Models and methods to characterise levonorgestrel release from intradermally administered contraceptives

Microneedle (MN)-based technologies have been proposed as a means to facilitate minimally invasive sustained delivery of long-acting hormonal contraceptives into the skin. Intradermal administration is a new route of delivery for these contraceptives and therefore no established laboratory methods o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug delivery and translational research 2022-02, Vol.12 (2), p.335-349
Hauptverfasser: Al Dalaty, Adnan, Gualeni, Benedetta, Coulman, Sion A., Birchall, James C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 349
container_issue 2
container_start_page 335
container_title Drug delivery and translational research
container_volume 12
creator Al Dalaty, Adnan
Gualeni, Benedetta
Coulman, Sion A.
Birchall, James C.
description Microneedle (MN)-based technologies have been proposed as a means to facilitate minimally invasive sustained delivery of long-acting hormonal contraceptives into the skin. Intradermal administration is a new route of delivery for these contraceptives and therefore no established laboratory methods or experimental models are available to predict dermal drug release and pharmacokinetics from candidate MN formulations. This study evaluates an in vitro release (IVR) medium and a medium supplemented with ex vivo human skin homogenate (SH) as potential laboratory models to investigate the dermal release characteristics of one such hormonal contraceptive that is being tested for MN delivery, levonorgestrel (LNG), and provides details of an accompanying novel two-step liquid–liquid drug extraction procedure and sensitive reversed-phase HPLC–UV assay. The extraction efficiency of LNG was 91.7 ± 3.06% from IVR medium and 84.6 ± 1.6% from the medium supplemented with SH. The HPLC–UV methodology had a limit of quantification of 0.005 µg/mL and linearity between 0.005 and 25 µg/mL. Extraction and detection methods for LNG were exemplified in both models using the well-characterised, commercially available sustained-release implant (Jadelle®). Sustained LNG release from the implant was detected in both media over 28 days. This study reports for the first time the use of biologically relevant release models and a rapid, reliable and sensitive methodology to determine release characteristics of LNG from intradermally administered long-acting drug delivery systems. Graphical abstract
doi_str_mv 10.1007/s13346-021-01091-5
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8724103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>34862590</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-3b63acbdb25d4795e59d951b56004d42e737809155800c0ad2e1beec02ffb2b3</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMottS-gAvJC4zmOpeNIMUbVNx04S5kkjOdKTOTkkwLfXtTR4tuDIQc8p__z8mH0DUlt5SQ7C5QzkWaEEYTQklBE3mGpowWJOGFyM9PNf-YoHkIGxKXSGlWZJdowkWeMlmQKarfnIU2YN1b3MFQOxvw4LCptddmAN8EwC3sXe_8GsLgocVxg47XlXcdbvrBawu-0217wNp2Td-E6AOLjTtqBrZDs4dwhS4q3QaYf58ztHp6XC1ekuX78-viYZkYIdIh4WXKtSltyaQVWSFBFraQtJRpHN8KBhnP8vhdKXNCDNGWAS0BDGFVVbKSz9D9GLvdlR1YA8cZWrX1Taf9QTndqL9K39Rq7fYqz5ighMcANgYY70LwUJ28lKgjeTWSV5G8-iKvZDTd_H71ZPnhHBv42BCi1K_Bq43b-T6C-C_2E6nBkxg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Models and methods to characterise levonorgestrel release from intradermally administered contraceptives</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Al Dalaty, Adnan ; Gualeni, Benedetta ; Coulman, Sion A. ; Birchall, James C.</creator><creatorcontrib>Al Dalaty, Adnan ; Gualeni, Benedetta ; Coulman, Sion A. ; Birchall, James C.</creatorcontrib><description>Microneedle (MN)-based technologies have been proposed as a means to facilitate minimally invasive sustained delivery of long-acting hormonal contraceptives into the skin. Intradermal administration is a new route of delivery for these contraceptives and therefore no established laboratory methods or experimental models are available to predict dermal drug release and pharmacokinetics from candidate MN formulations. This study evaluates an in vitro release (IVR) medium and a medium supplemented with ex vivo human skin homogenate (SH) as potential laboratory models to investigate the dermal release characteristics of one such hormonal contraceptive that is being tested for MN delivery, levonorgestrel (LNG), and provides details of an accompanying novel two-step liquid–liquid drug extraction procedure and sensitive reversed-phase HPLC–UV assay. The extraction efficiency of LNG was 91.7 ± 3.06% from IVR medium and 84.6 ± 1.6% from the medium supplemented with SH. The HPLC–UV methodology had a limit of quantification of 0.005 µg/mL and linearity between 0.005 and 25 µg/mL. Extraction and detection methods for LNG were exemplified in both models using the well-characterised, commercially available sustained-release implant (Jadelle®). Sustained LNG release from the implant was detected in both media over 28 days. This study reports for the first time the use of biologically relevant release models and a rapid, reliable and sensitive methodology to determine release characteristics of LNG from intradermally administered long-acting drug delivery systems. Graphical abstract</description><identifier>ISSN: 2190-393X</identifier><identifier>EISSN: 2190-3948</identifier><identifier>DOI: 10.1007/s13346-021-01091-5</identifier><identifier>PMID: 34862590</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Contraceptive Agents, Female ; Drug Delivery Systems ; Drug Liberation ; Female ; Humans ; Levonorgestrel - pharmacokinetics ; Original ; Original Article ; Pharmaceutical Sciences/Technology</subject><ispartof>Drug delivery and translational research, 2022-02, Vol.12 (2), p.335-349</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-3b63acbdb25d4795e59d951b56004d42e737809155800c0ad2e1beec02ffb2b3</citedby><cites>FETCH-LOGICAL-c446t-3b63acbdb25d4795e59d951b56004d42e737809155800c0ad2e1beec02ffb2b3</cites><orcidid>0000-0002-1277-7584 ; 0000-0002-5216-1151 ; 0000-0001-8521-6924 ; 0000-0003-3761-632X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13346-021-01091-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13346-021-01091-5$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34862590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al Dalaty, Adnan</creatorcontrib><creatorcontrib>Gualeni, Benedetta</creatorcontrib><creatorcontrib>Coulman, Sion A.</creatorcontrib><creatorcontrib>Birchall, James C.</creatorcontrib><title>Models and methods to characterise levonorgestrel release from intradermally administered contraceptives</title><title>Drug delivery and translational research</title><addtitle>Drug Deliv. and Transl. Res</addtitle><addtitle>Drug Deliv Transl Res</addtitle><description>Microneedle (MN)-based technologies have been proposed as a means to facilitate minimally invasive sustained delivery of long-acting hormonal contraceptives into the skin. Intradermal administration is a new route of delivery for these contraceptives and therefore no established laboratory methods or experimental models are available to predict dermal drug release and pharmacokinetics from candidate MN formulations. This study evaluates an in vitro release (IVR) medium and a medium supplemented with ex vivo human skin homogenate (SH) as potential laboratory models to investigate the dermal release characteristics of one such hormonal contraceptive that is being tested for MN delivery, levonorgestrel (LNG), and provides details of an accompanying novel two-step liquid–liquid drug extraction procedure and sensitive reversed-phase HPLC–UV assay. The extraction efficiency of LNG was 91.7 ± 3.06% from IVR medium and 84.6 ± 1.6% from the medium supplemented with SH. The HPLC–UV methodology had a limit of quantification of 0.005 µg/mL and linearity between 0.005 and 25 µg/mL. Extraction and detection methods for LNG were exemplified in both models using the well-characterised, commercially available sustained-release implant (Jadelle®). Sustained LNG release from the implant was detected in both media over 28 days. This study reports for the first time the use of biologically relevant release models and a rapid, reliable and sensitive methodology to determine release characteristics of LNG from intradermally administered long-acting drug delivery systems. Graphical abstract</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Contraceptive Agents, Female</subject><subject>Drug Delivery Systems</subject><subject>Drug Liberation</subject><subject>Female</subject><subject>Humans</subject><subject>Levonorgestrel - pharmacokinetics</subject><subject>Original</subject><subject>Original Article</subject><subject>Pharmaceutical Sciences/Technology</subject><issn>2190-393X</issn><issn>2190-3948</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMottS-gAvJC4zmOpeNIMUbVNx04S5kkjOdKTOTkkwLfXtTR4tuDIQc8p__z8mH0DUlt5SQ7C5QzkWaEEYTQklBE3mGpowWJOGFyM9PNf-YoHkIGxKXSGlWZJdowkWeMlmQKarfnIU2YN1b3MFQOxvw4LCptddmAN8EwC3sXe_8GsLgocVxg47XlXcdbvrBawu-0217wNp2Td-E6AOLjTtqBrZDs4dwhS4q3QaYf58ztHp6XC1ekuX78-viYZkYIdIh4WXKtSltyaQVWSFBFraQtJRpHN8KBhnP8vhdKXNCDNGWAS0BDGFVVbKSz9D9GLvdlR1YA8cZWrX1Taf9QTndqL9K39Rq7fYqz5ighMcANgYY70LwUJ28lKgjeTWSV5G8-iKvZDTd_H71ZPnhHBv42BCi1K_Bq43b-T6C-C_2E6nBkxg</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Al Dalaty, Adnan</creator><creator>Gualeni, Benedetta</creator><creator>Coulman, Sion A.</creator><creator>Birchall, James C.</creator><general>Springer US</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1277-7584</orcidid><orcidid>https://orcid.org/0000-0002-5216-1151</orcidid><orcidid>https://orcid.org/0000-0001-8521-6924</orcidid><orcidid>https://orcid.org/0000-0003-3761-632X</orcidid></search><sort><creationdate>20220201</creationdate><title>Models and methods to characterise levonorgestrel release from intradermally administered contraceptives</title><author>Al Dalaty, Adnan ; Gualeni, Benedetta ; Coulman, Sion A. ; Birchall, James C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-3b63acbdb25d4795e59d951b56004d42e737809155800c0ad2e1beec02ffb2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Contraceptive Agents, Female</topic><topic>Drug Delivery Systems</topic><topic>Drug Liberation</topic><topic>Female</topic><topic>Humans</topic><topic>Levonorgestrel - pharmacokinetics</topic><topic>Original</topic><topic>Original Article</topic><topic>Pharmaceutical Sciences/Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al Dalaty, Adnan</creatorcontrib><creatorcontrib>Gualeni, Benedetta</creatorcontrib><creatorcontrib>Coulman, Sion A.</creatorcontrib><creatorcontrib>Birchall, James C.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug delivery and translational research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al Dalaty, Adnan</au><au>Gualeni, Benedetta</au><au>Coulman, Sion A.</au><au>Birchall, James C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Models and methods to characterise levonorgestrel release from intradermally administered contraceptives</atitle><jtitle>Drug delivery and translational research</jtitle><stitle>Drug Deliv. and Transl. Res</stitle><addtitle>Drug Deliv Transl Res</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>12</volume><issue>2</issue><spage>335</spage><epage>349</epage><pages>335-349</pages><issn>2190-393X</issn><eissn>2190-3948</eissn><abstract>Microneedle (MN)-based technologies have been proposed as a means to facilitate minimally invasive sustained delivery of long-acting hormonal contraceptives into the skin. Intradermal administration is a new route of delivery for these contraceptives and therefore no established laboratory methods or experimental models are available to predict dermal drug release and pharmacokinetics from candidate MN formulations. This study evaluates an in vitro release (IVR) medium and a medium supplemented with ex vivo human skin homogenate (SH) as potential laboratory models to investigate the dermal release characteristics of one such hormonal contraceptive that is being tested for MN delivery, levonorgestrel (LNG), and provides details of an accompanying novel two-step liquid–liquid drug extraction procedure and sensitive reversed-phase HPLC–UV assay. The extraction efficiency of LNG was 91.7 ± 3.06% from IVR medium and 84.6 ± 1.6% from the medium supplemented with SH. The HPLC–UV methodology had a limit of quantification of 0.005 µg/mL and linearity between 0.005 and 25 µg/mL. Extraction and detection methods for LNG were exemplified in both models using the well-characterised, commercially available sustained-release implant (Jadelle®). Sustained LNG release from the implant was detected in both media over 28 days. This study reports for the first time the use of biologically relevant release models and a rapid, reliable and sensitive methodology to determine release characteristics of LNG from intradermally administered long-acting drug delivery systems. Graphical abstract</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34862590</pmid><doi>10.1007/s13346-021-01091-5</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-1277-7584</orcidid><orcidid>https://orcid.org/0000-0002-5216-1151</orcidid><orcidid>https://orcid.org/0000-0001-8521-6924</orcidid><orcidid>https://orcid.org/0000-0003-3761-632X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2190-393X
ispartof Drug delivery and translational research, 2022-02, Vol.12 (2), p.335-349
issn 2190-393X
2190-3948
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8724103
source MEDLINE; SpringerNature Journals
subjects Biomedical and Life Sciences
Biomedicine
Contraceptive Agents, Female
Drug Delivery Systems
Drug Liberation
Female
Humans
Levonorgestrel - pharmacokinetics
Original
Original Article
Pharmaceutical Sciences/Technology
title Models and methods to characterise levonorgestrel release from intradermally administered contraceptives
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A02%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Models%20and%20methods%20to%20characterise%20levonorgestrel%20release%20from%20intradermally%20administered%20contraceptives&rft.jtitle=Drug%20delivery%20and%20translational%20research&rft.au=Al%20Dalaty,%20Adnan&rft.date=2022-02-01&rft.volume=12&rft.issue=2&rft.spage=335&rft.epage=349&rft.pages=335-349&rft.issn=2190-393X&rft.eissn=2190-3948&rft_id=info:doi/10.1007/s13346-021-01091-5&rft_dat=%3Cpubmed_cross%3E34862590%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34862590&rfr_iscdi=true